HKPD (Cellyan Biotechnology Co) Revenue: $16.36 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKPD Cellyan Biotechnology Co Ltd HKPD
21 GF Score
Price $0.39
! 2 Warning Signs
View Full Analysis

What is Cellyan Biotechnology Co Revenue?

Cellyan Biotechnology Co HKPD -7.93% 21 Revenue is $16.36 Mil as of Sep. 2025. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Cellyan Biotechnology Co's revenue for the six months ended in Sep. 2025 was $7.14 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2025 was $16.36 Mil. Cellyan Biotechnology Co's Revenue per Share for the six months ended in Sep. 2025 was $0.65. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 was $1.49.

Warning Sign:

Cellyan Biotechnology Co Ltd revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Cellyan Biotechnology Co was -21.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Cellyan Biotechnology Co  (NAS:HKPD) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Cellyan Biotechnology Co Revenue Related Terms

Cellyan Biotechnology Co Revenue Historical Data

* Premium members only.

The historical data trend for Cellyan Biotechnology Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellyan Biotechnology Co Revenue Chart

Cellyan Biotechnology Co Annual Data
Trend Mar23 Mar24 Mar25
Revenue
12.56 16.69 20.31

Cellyan Biotechnology Co Semi-Annual Data
Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Revenue Get a 7-Day Free Trial 7.01 9.68 11.09 9.22 7.14

HKPD vs COSM, SNYR, YI: Revenue Comparison

For the Medical Distribution subindustry, Cellyan Biotechnology Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellyan Biotechnology Co Revenue vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Revenue distribution charts can be found below:

* The bar in red indicates where Cellyan Biotechnology Co's Revenue falls into.


HKPD
21GF Score
Cellyan Biotechnology Co Ltd HKPD
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellyan Biotechnology Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $16.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $16.36 Mil mean?
Cellyan Biotechnology Co (HKPD) has a Revenue of $16.36 Mil as of Sep. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Cellyan Biotechnology Co and its competitors.
Is Cellyan Biotechnology Co's Revenue too high?
Cellyan Biotechnology Co's current Revenue is $16.36 Mil. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Revenue compare to COSM and SNYR?
Cellyan Biotechnology Co's Revenue of $16.36 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Distribution company?
A good Revenue depends on the Medical Distribution industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Cellyan Biotechnology Co and its competitors. Cellyan Biotechnology Co's current Revenue is $16.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Revenue of $16.36 Mil. The current Revenue is $16.36 Mil. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Revenue is $16.36 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellyan Biotechnology Co Business Description

Address 13 Ko Fai Road, Room B1, 5th Floor, Well Town Industrial Building, Yau Tong, Kowloon, Hong Kong, HKG
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score

Get the complete analysis for HKPD

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price